2013 - Fellow of the American Association for the Advancement of Science (AAAS)
1996 - Fellow of the American Statistical Association (ASA)
Barry R. Davis spends much of his time researching Internal medicine, Cardiology, Myocardial infarction, Surgery and Chlorthalidone. His Internal medicine research includes themes of Placebo and Endocrinology. His research investigates the link between Cardiology and topics such as Doxazosin that cross with problems in Lipid lowering.
His research integrates issues of Captopril and Ventricular Ejection Fraction in his study of Myocardial infarction. The various areas that he examines in his Surgery study include Clinical trial, Incidence, Rheumatoid arthritis and Confidence interval. His work in Chlorthalidone addresses subjects such as Diabetes mellitus, which are connected to disciplines such as Randomized controlled trial.
His scientific interests lie mostly in Internal medicine, Cardiology, Chlorthalidone, Blood pressure and Amlodipine. His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Surgery. His Cardiology research is multidisciplinary, incorporating perspectives in Diabetes mellitus, Randomized controlled trial, Disease, Hazard ratio and Risk factor.
His Chlorthalidone research integrates issues from Antihypertensive drug, Atenolol, Doxazosin and Thiazide. His research in Blood pressure intersects with topics in Meta-analysis, Placebo and Emergency medicine. Barry R. Davis interconnects Lisinopril, Calcium channel blocker, Pharmacology and Renal function in the investigation of issues within Amlodipine.
His primary scientific interests are in Internal medicine, Cardiology, Blood pressure, Amlodipine and Stroke. Internal medicine is closely attributed to Diabetes mellitus in his work. The study incorporates disciplines such as Clinical trial, Left ventricular hypertrophy, Diuretic, Systolic hypertension and Risk factor in addition to Cardiology.
His biological study spans a wide range of topics, including Meta-analysis, Randomized controlled trial and Disease. His Stroke study combines topics in areas such as Coronary heart disease, Physical therapy, Sickle cell anemia and Prospective cohort study. His Chlorthalidone research is multidisciplinary, relying on both Lisinopril and Cohort.
Barry R. Davis mostly deals with Internal medicine, Blood pressure, Cardiology, Stroke and Randomized controlled trial. His Internal medicine study frequently links to other fields, such as Diabetes mellitus. Barry R. Davis has researched Cardiology in several fields, including Predictive value of tests, Disease, Diastole and Diuretic.
His Myocardial infarction research incorporates themes from Statin and Physical therapy. His Amlodipine study integrates concerns from other disciplines, such as Chlorthalidone and Risk factor. As a part of the same scientific family, Barry R. Davis mostly works in the field of Chlorthalidone, focusing on Lisinopril and, on occasion, Surgery.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
F. M. Sacks;M. A. Pfeffer;L. A. Moye;J. L. Rouleau.
The New England Journal of Medicine (1996)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Curt D. Furberg;Jackson T. Wright;Barry R Davis;Jeffrey A. Cutler.
EFFECT OF CAPTOPRIL ON MORTALITY AND MORBIDITY IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION. RESULTS OF THE SURVIVAL AND VENTRICULAR ENLARGEMENT TRIAL
Marc A. Pfeffer;Eugene Braunwald;Lemuel A. Moyé;Lofty Basta.
The New England Journal of Medicine (1992)
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Claire Bombardier;Loren Laine;Alise Reicin;Deborah Shapiro.
The New England Journal of Medicine (2000)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar;David Preiss;Heather M Murray;Paul Welsh.
The Lancet (2010)
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
Barry R Davis.
Major Outcomes in Moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care
Curt D. Furberg;Jackson T. Wright;Barry R. Davis;Jeffrey A. Cutler.
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
William C. Cushman;Charles E. Ford;Jeffrey A. Cutler;Karen L. Margolis.
Journal of Clinical Hypertension (2002)
Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial
Ronald B. Goldberg;Margot J. Mellies;Frank M. Sacks;Lemuel A. Moyé.
Effect of Diuretic-Based Antihypertensive Treatment on Cardiovascular Disease Risk in Older Diabetic Patients With Isolated Systolic Hypertension
J. David Curb;Sara L. Pressel;Jeffrey A. Cutler;Peter J. Savage.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: